Bristol-Myers Squibb Co

BMY: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
w&bLOCK|!BzLOCK|xl#^xZp

Bristol-Myers Squibb Earnings: Guidance Raised on Currency Tailwind but Key Data Still to Come

Bristol-Myers Squibb reported a 6% decline in revenue in the first quarter. Management raised guidance to $46.3 billion in revenue and $6.85 in non-GAAP EPS at the midpoint, accounting for a $500 million currency tailwind and slower-than-expected declines for hematology drug Revlimid.

Sponsor Center